Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Selective estrogen receptor modulators (SERMs) like tamoxifene and raloxifene are now well-established therapeutics, and new agents such as bazedoxifene and ospemifene have recently been introduced. These new agents have unique tissue-specific profiles that allow for a customization of therapeutic effect. In this review, the profiles of bazedoxifene and ospemifene will be compared and discussed relevant to their place in clinical practice.

SERMs: Where Are We in 2014?